Among 11 analysts covering Legacy Reserves (NASDAQ:LGCY), 0 have Buy rating, 4 Sell and 7 Hold. Therefore 0 are positive. Legacy Reserves had 21 analyst reports since August 7, 2015 according to SRatingsIntel. Barclays Capital maintained it with “Equal Weight” rating and $3 target in Wednesday, September 30 report. UBS downgraded the stock to “Sell” rating in Wednesday, September 9 report. On Friday, August 7 the stock rating was maintained by Wunderlich with “Buy”. The firm earned “Market Perform” rating on Wednesday, January 27 by FBR Capital. FBR Capital maintained it with “Outperform” rating and $8 target in Monday, October 12 report. The company was maintained on Thursday, September 29 by Citigroup. The stock of Legacy Reserves LP (NASDAQ:LGCY) has “Underperform” rating given on Wednesday, October 21 by Bank of America. The firm has “Neutral” rating given on Monday, March 21 by Citigroup. The firm earned “Sell” rating on Monday, September 19 by Stifel Nicolaus. The stock of Legacy Reserves LP (NASDAQ:LGCY) has “Outperform” rating given on Wednesday, November 18 by FBR Capital. See Legacy Reserves LP (NASDAQ:LGCY) latest ratings:
26/10/2016 Broker: Stifel Nicolaus Old Rating: Sell New Rating: Hold Old Target: $0.50 New Target: $1.75 Upgrade
29/09/2016 Broker: Citigroup Rating: Neutral Old Target: $2.00 New Target: $1.50 Maintain
The stock of Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) is a huge mover today! About 69,328 shares traded or 178.55% up from the average. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) has risen 256.48% since August 16, 2016 and is uptrending. It has outperformed by 248.66% the S&P500.The move comes after 6 months positive chart setup for the $7.75 million company. It was reported on Mar, 23 by Barchart.com. We have $4.35 PT which if reached, will make NASDAQ:ROSG worth $232,500 more.
Since February 27, 2017, it had 1 buying transaction, and 2 insider sales for $1.90 million activity. Shares for $1,879 were bought by Vann Kyle D. On Monday, February 27 the insider Brown Dale A sold $952,884. $952,884 worth of Legacy Reserves LP (NASDAQ:LGCY) was sold by Brown Cary D.
About 125,249 shares traded. Legacy Reserves LP (NASDAQ:LGCY) has risen 13.33% since August 16, 2016 and is uptrending. It has outperformed by 5.51% the S&P500.
Investors sentiment increased to 0.63 in 2016 Q4. Its up 0.20, from 0.43 in 2016Q3. It improved, as 9 investors sold Legacy Reserves LP shares while 15 reduced holdings. 8 funds opened positions while 7 raised stakes. 14.63 million shares or 12.10% more from 13.05 million shares in 2016Q3 were reported. Manufacturers Life Insurance The invested 0% in Legacy Reserves LP (NASDAQ:LGCY). Oxbow Advisors Limited Liability invested in 49,023 shares. Raymond James Financial Ser holds 0% or 18,812 shares. Syntal Ptnrs Limited Liability has 18,840 shares for 0.04% of their portfolio. Bessemer Gru Incorporated holds 0% or 3,000 shares in its portfolio. Creative Planning invested in 9,801 shares. Finemark Natl Bank And Trust has invested 0% in Legacy Reserves LP (NASDAQ:LGCY). Citadel Advsrs Limited Liability Company has invested 0% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). Commonwealth Fincl Svcs Ltd Liability invested 0% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). Gsa Cap Prns Ltd Liability Partnership invested 0.02% in Legacy Reserves LP (NASDAQ:LGCY). Credit Suisse Ag reported 1.80M shares. Susquehanna Gp Llp accumulated 69,534 shares. Walleye Trading Limited Liability Company reported 0% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). Oppenheimer And Inc stated it has 0.01% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). 20,000 are owned by Cetera Advisors Lc.
Legacy Reserves LP is a master limited partnership company. The company has market cap of $129.60 million. The Firm focuses on the acquisition and development of oil and natural gas properties located in the Permian Basin, East Texas, Rocky Mountain and Mid-Continent regions of the United States. It currently has negative earnings. As of December 31, 2016, the Company had proved reserves of approximately 144.8 million barrels of crude oil equivalent (MMBoe), of which 72% were natural gas, 28% were oil and natural gas liquids (NGLs) and 94% were classified as proved developed producing.
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid , micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The company has market cap of $7.75 million. It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. It currently has negative earnings. The Company’s therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project.
